JP2015536667A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015536667A5 JP2015536667A5 JP2015544542A JP2015544542A JP2015536667A5 JP 2015536667 A5 JP2015536667 A5 JP 2015536667A5 JP 2015544542 A JP2015544542 A JP 2015544542A JP 2015544542 A JP2015544542 A JP 2015544542A JP 2015536667 A5 JP2015536667 A5 JP 2015536667A5
- Authority
- JP
- Japan
- Prior art keywords
- score
- biomarker panel
- subject
- expression
- biomarker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 59
- 239000000523 sample Substances 0.000 claims 35
- 238000000034 method Methods 0.000 claims 33
- 230000001772 anti-angiogenic effect Effects 0.000 claims 25
- 239000003814 drug Substances 0.000 claims 23
- 229940124597 therapeutic agent Drugs 0.000 claims 23
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 11
- 238000004393 prognosis Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 238000002493 microarray Methods 0.000 claims 5
- 102100039435 C-X-C motif chemokine 17 Human genes 0.000 claims 4
- -1 CXCR2P1 Proteins 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 101000889048 Homo sapiens C-X-C motif chemokine 17 Proteins 0.000 claims 4
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims 4
- 101000575378 Homo sapiens Microfibrillar-associated protein 2 Proteins 0.000 claims 4
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 claims 4
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 claims 4
- 101000831866 Homo sapiens Transmembrane protein 45A Proteins 0.000 claims 4
- 102100023915 Insulin Human genes 0.000 claims 4
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims 4
- 108010072582 Matrilin Proteins Proteins 0.000 claims 4
- 102100033670 Matrilin-3 Human genes 0.000 claims 4
- 102100025599 Microfibrillar-associated protein 2 Human genes 0.000 claims 4
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 claims 4
- 108091006277 SLC5A1 Proteins 0.000 claims 4
- 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 4
- 102100022415 Transcription factor SOX-11 Human genes 0.000 claims 4
- 102100024186 Transmembrane protein 45A Human genes 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 238000010837 poor prognosis Methods 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 238000003018 immunoassay Methods 0.000 claims 3
- 238000003753 real-time PCR Methods 0.000 claims 3
- 230000004043 responsiveness Effects 0.000 claims 3
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 2
- ZHBXLZQQVCDGPA-UHFFFAOYSA-N 5-[(1,3-dioxo-2-benzofuran-5-yl)sulfonyl]-2-benzofuran-1,3-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC(S(=O)(=O)C=2C=C3C(=O)OC(C3=CC=2)=O)=C1 ZHBXLZQQVCDGPA-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 230000008236 biological pathway Effects 0.000 claims 2
- 230000031018 biological processes and functions Effects 0.000 claims 2
- 229960002412 cediranib Drugs 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 2
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 claims 1
- 102000009840 Angiopoietins Human genes 0.000 claims 1
- 108010009906 Angiopoietins Proteins 0.000 claims 1
- 102400000068 Angiostatin Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 102000003916 Arrestin Human genes 0.000 claims 1
- 108090000328 Arrestin Proteins 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 102100024155 Cadherin-11 Human genes 0.000 claims 1
- 102400000730 Canstatin Human genes 0.000 claims 1
- 101800000626 Canstatin Proteins 0.000 claims 1
- 102100031186 Chromogranin-A Human genes 0.000 claims 1
- 102100023708 Coiled-coil domain-containing protein 80 Human genes 0.000 claims 1
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 claims 1
- 102100033825 Collagen alpha-1(XI) chain Human genes 0.000 claims 1
- 102100027995 Collagenase 3 Human genes 0.000 claims 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 1
- 102400001047 Endostatin Human genes 0.000 claims 1
- 108010079505 Endostatins Proteins 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 102100037156 Gap junction beta-2 protein Human genes 0.000 claims 1
- 101710088083 Glomulin Proteins 0.000 claims 1
- 102100033424 Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Human genes 0.000 claims 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 claims 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 claims 1
- 101000978383 Homo sapiens Coiled-coil domain-containing protein 80 Proteins 0.000 claims 1
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 claims 1
- 101000710623 Homo sapiens Collagen alpha-1(XI) chain Proteins 0.000 claims 1
- 101000577887 Homo sapiens Collagenase 3 Proteins 0.000 claims 1
- 101001027128 Homo sapiens Fibronectin Proteins 0.000 claims 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 claims 1
- 101000997966 Homo sapiens Glutamine-fructose-6-phosphate aminotransferase [isomerizing] 2 Proteins 0.000 claims 1
- 101000852489 Homo sapiens Inositol 1,4,5-triphosphate receptor associated 1 Proteins 0.000 claims 1
- 101001095308 Homo sapiens Periostin Proteins 0.000 claims 1
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 claims 1
- 101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 claims 1
- 101000873646 Homo sapiens Protein bicaudal C homolog 1 Proteins 0.000 claims 1
- 101001060862 Homo sapiens Ras-related protein Rab-31 Proteins 0.000 claims 1
- 101000864786 Homo sapiens Secreted frizzled-related protein 2 Proteins 0.000 claims 1
- 101000633605 Homo sapiens Thrombospondin-2 Proteins 0.000 claims 1
- 101000787917 Homo sapiens Transmembrane protein 200A Proteins 0.000 claims 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 claims 1
- 102100027004 Inhibin beta A chain Human genes 0.000 claims 1
- 102100036344 Inositol 1,4,5-triphosphate receptor associated 1 Human genes 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 1
- 102100037765 Periostin Human genes 0.000 claims 1
- 102100030564 Peroxisomal membrane protein 2 Human genes 0.000 claims 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 1
- 102100035896 Protein bicaudal C homolog 1 Human genes 0.000 claims 1
- 102100027838 Ras-related protein Rab-31 Human genes 0.000 claims 1
- 102100030054 Secreted frizzled-related protein 2 Human genes 0.000 claims 1
- 102000002938 Thrombospondin Human genes 0.000 claims 1
- 108060008245 Thrombospondin Proteins 0.000 claims 1
- 102100029529 Thrombospondin-2 Human genes 0.000 claims 1
- 102100025940 Transmembrane protein 200A Human genes 0.000 claims 1
- 102400000731 Tumstatin Human genes 0.000 claims 1
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 claims 1
- 229960002833 aflibercept Drugs 0.000 claims 1
- 108010081667 aflibercept Proteins 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 230000003527 anti-angiogenesis Effects 0.000 claims 1
- 238000011122 anti-angiogenic therapy Methods 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 claims 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 108010019691 inhibin beta A subunit Proteins 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- 229960001346 nilotinib Drugs 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960000639 pazopanib Drugs 0.000 claims 1
- 229960002633 ramucirumab Drugs 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229940034785 sutent Drugs 0.000 claims 1
- 229940069905 tasigna Drugs 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 108010075758 trebananib Proteins 0.000 claims 1
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims 1
- 108010060757 vasostatin Proteins 0.000 claims 1
- 229940069559 votrient Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732761P | 2012-12-03 | 2012-12-03 | |
| US61/732,761 | 2012-12-03 | ||
| PCT/GB2013/053202 WO2014087156A1 (en) | 2012-12-03 | 2013-12-03 | Molecular diagnostic test for cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015536667A JP2015536667A (ja) | 2015-12-24 |
| JP2015536667A5 true JP2015536667A5 (https=) | 2017-01-19 |
Family
ID=49780086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544542A Pending JP2015536667A (ja) | 2012-12-03 | 2013-12-03 | 癌のための分子診断検査 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11091809B2 (https=) |
| EP (1) | EP2925885B1 (https=) |
| JP (1) | JP2015536667A (https=) |
| KR (1) | KR20150090246A (https=) |
| CN (1) | CN105102631A (https=) |
| AU (1) | AU2013353839A1 (https=) |
| CA (1) | CA2893033A1 (https=) |
| HK (1) | HK1214633A1 (https=) |
| IL (1) | IL239196A0 (https=) |
| MX (1) | MX2015006955A (https=) |
| SG (1) | SG11201504023SA (https=) |
| WO (1) | WO2014087156A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013031019A2 (pt) | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| MX2015006955A (es) | 2012-12-03 | 2016-01-25 | Almac Diagnostics Ltd | Prueba de diagnostico molecular para cancer. |
| US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
| US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| GB201409479D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| GB201409478D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Pro-angiogenic signature |
| GB201409476D0 (en) * | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular subtype for use in prognosis |
| WO2016011052A1 (en) * | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
| CN104212440B (zh) * | 2014-09-03 | 2016-03-30 | 无锡艾德美特生物科技有限公司 | 一类喹唑啉类荧光探针及其制备和应用 |
| BR112017010788A2 (pt) * | 2014-12-23 | 2017-12-26 | Genentech Inc | métodos de identificação de um paciente com câncer e de identificação de um paciente que sofre de câncer que pode beneficiar da administração de um antagonista de vegf, método de tratamento de um paciente com câncer e método para determinar o estágio de câncer de ovário |
| JP6942135B2 (ja) * | 2016-01-25 | 2021-09-29 | サノフイＳａｎｏｆｉ | 血漿バイオマーカーのレベルを測定することによる、がんに罹患していることが疑われる患者のアフリベルセプトによる治療の転帰を予測するための方法 |
| AU2017248766A1 (en) * | 2016-04-15 | 2018-11-01 | Genentech, Inc. | Methods for monitoring and treating cancer |
| WO2017201036A1 (en) * | 2016-05-17 | 2017-11-23 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| JP6899848B2 (ja) | 2016-12-28 | 2021-07-07 | 公益財団法人がん研究会 | 抗ｖｅｇｆｒ−２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット |
| CN110546277B (zh) | 2017-03-01 | 2024-06-11 | 豪夫迈·罗氏有限公司 | 用于癌症的诊断和治疗方法 |
| EP3879535B1 (en) * | 2017-06-13 | 2024-12-11 | BostonGene Corporation | Systems and methods for identifying cancer treatments from normalized biomarker scores |
| US10636512B2 (en) * | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| EP3652663A4 (en) * | 2017-07-14 | 2021-04-21 | Cofactor Genomics, Inc. | NEXT GENERATION IMMUNONCOLOGICAL APPLICATIONS BY SEQUENCING |
| CN107621545B (zh) * | 2017-07-26 | 2019-10-11 | 东南大学 | Bicc1蛋白对精神疾病诊断的新用途 |
| WO2019074920A1 (en) * | 2017-10-10 | 2019-04-18 | Oncocyte Corporation | METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER |
| DE112018006190T5 (de) * | 2017-12-04 | 2020-08-20 | Nantomics, Llc | Subtypisierung von tnbc und methoden |
| CN108524937B (zh) * | 2018-05-11 | 2020-05-05 | 中南大学湘雅三医院 | Mrvi1-as1作为靶位点在制备治疗鼻咽癌紫杉醇化疗增敏药物中的应用 |
| EP3843638A4 (en) * | 2018-08-31 | 2022-05-18 | Seno Medical Instruments, Inc. | METHODS AND SYSTEMS FOR DETERMINING MOLECULAR CANCER SUBTYPES BASED ON ULTRASOUND AND/OR OPTOACOUSTIC (OA/US) PROPERTIES |
| CN109585011A (zh) * | 2018-10-26 | 2019-04-05 | 朱海燕 | 胸痛患者的病症诊断方法及机器可读存储介质 |
| WO2020223576A1 (en) * | 2019-04-30 | 2020-11-05 | Chondrial Therapeutics, Inc. | Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy |
| CN110358827A (zh) * | 2019-07-09 | 2019-10-22 | 中国人民解放军第四军医大学 | Vmp1基因在病理诊断胶质母细胞瘤中的应用及其试剂盒的制备 |
| WO2021034091A1 (ko) * | 2019-08-19 | 2021-02-25 | 재단법인 아산사회복지재단 | 교모세포종의 진단 방법 |
| IT201900023946A1 (it) * | 2019-12-13 | 2021-06-13 | Complexdata S R L | Metodo per determinare una prognosi di sopravvivenza a lungo termine di pazienti di cancro al seno, sulla base di algoritmi che modellizzano reti biologiche |
| CN111105843B (zh) * | 2019-12-31 | 2023-07-21 | 杭州纽安津生物科技有限公司 | 一种hlai型分子与多肽的亲和力预测方法 |
| CN111735949B (zh) * | 2020-07-17 | 2023-07-21 | 北京信诺卫康科技有限公司 | Wnt7a和CA125联合用作早期卵巢癌生物标志物以及试剂盒 |
| CN112266961B (zh) * | 2020-10-29 | 2023-05-12 | 中山大学附属第六医院 | Tsg-6基因在预测结直肠癌转移及预后方面的应用 |
| CN112592397B (zh) * | 2020-12-31 | 2022-08-30 | 上海市胸科医院 | Ccdc80来源的多肽及其用途 |
| CN113035298B (zh) * | 2021-04-02 | 2023-06-20 | 南京信息工程大学 | 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法 |
| KR102897399B1 (ko) * | 2021-04-12 | 2025-12-08 | 연세대학교 산학협력단 | 유방암 진단을 위한 신규 바이오마커 |
| US20250266162A1 (en) * | 2021-05-13 | 2025-08-21 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Method of targeted multi-panel approach and tiered a.i. use for differential diagnosis and prognosis |
| CN116243003B (zh) * | 2023-02-20 | 2025-12-09 | 东莞市滨海湾中心医院(东莞市太平人民医院、东莞市第五人民医院) | Smox在制备结直肠癌诊断或预后预测产品中的应用 |
| CN116482367A (zh) * | 2023-05-04 | 2023-07-25 | 中国中医科学院望京医院(中国中医科学院骨伤科研究所) | 一种联合mSEPT9检测和生物标志物的结直肠癌检测方法 |
| CN116519954B (zh) * | 2023-06-28 | 2023-10-27 | 杭州广科安德生物科技有限公司 | 一种结直肠癌检测模型构建方法、系统及生物标志物 |
| CN117089621B (zh) * | 2023-09-28 | 2024-06-25 | 上海爱谱蒂康生物科技有限公司 | 生物标志物组合及其在预测结直肠癌疗效中的应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
| US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US5547839A (en) | 1989-06-07 | 1996-08-20 | Affymax Technologies N.V. | Sequencing of surface immobilized polymers utilizing microflourescence detection |
| US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
| US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| EP0430881A3 (en) | 1989-11-29 | 1991-10-23 | Ciba-Geigy Ag | Photochromic compounds, process for their preparation and their use |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
| ATE173767T1 (de) | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | Proben zusammensetzung und verfahren |
| US5503980A (en) | 1992-11-06 | 1996-04-02 | Trustees Of Boston University | Positional sequencing by hybridization |
| US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
| US5470710A (en) | 1993-10-22 | 1995-11-28 | University Of Utah | Automated hybridization/imaging device for fluorescent multiplex DNA sequencing |
| GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
| US6946442B2 (en) | 1994-11-30 | 2005-09-20 | Asif Syed Ahmed | Method of hastening cervical ripening |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| US5661028A (en) | 1995-09-29 | 1997-08-26 | Lockheed Martin Energy Systems, Inc. | Large scale DNA microsequencing device |
| JP2002515738A (ja) | 1996-01-23 | 2002-05-28 | アフィメトリックス，インコーポレイティド | 核酸分析法 |
| US6680175B2 (en) | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| US6998234B2 (en) | 2000-11-03 | 2006-02-14 | Oncotech, Inc. | Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells |
| WO2003096981A2 (en) | 2002-05-15 | 2003-11-27 | Seul, Kyung, Hwan | Method of modulating angiogenesis |
| AU2003281325A1 (en) | 2002-07-02 | 2004-01-23 | The Johns Hopkins University | Secreted and cytoplasmic tumor endothelial markers |
| MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
| WO2004108896A2 (en) * | 2003-06-03 | 2004-12-16 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors |
| CN102321584B (zh) | 2003-12-31 | 2014-01-08 | 宾夕法尼亚州研究基金会 | 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法 |
| US20080113874A1 (en) | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
| CA2563074C (en) | 2004-04-09 | 2014-05-20 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| AU2005236075A1 (en) * | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
| EP1756306A2 (en) | 2004-05-14 | 2007-02-28 | Ludwig Institute For Cancer Research | Identification and characterization of a subset of glioblastomas sensitive to treatment with imatinib |
| AU2005263972A1 (en) | 2004-07-23 | 2006-01-26 | Astrazeneca Ab | Method of predicting the responsiveness of a tumor to erbB receptor drugs |
| EP1815021A2 (en) | 2004-11-03 | 2007-08-08 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
| US7862995B2 (en) * | 2004-12-10 | 2011-01-04 | Targeted Molecular Diagnostics | Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor |
| CA2601157A1 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| EP1937837A2 (en) | 2005-07-29 | 2008-07-02 | Siemens Healthcare Diagnostics Inc. | Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies |
| AU2006292278B2 (en) | 2005-09-20 | 2012-03-08 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US7919261B2 (en) | 2005-12-05 | 2011-04-05 | Merck Sharp & Dohme Corp. | Methods for predicting treatment response based on the expression profiles of protein and transcription biomarkers |
| WO2007067500A2 (en) | 2005-12-05 | 2007-06-14 | Genomic Health, Inc. | Predictors of patient response to treatment with egfr inhibitors |
| EP2363711A1 (en) | 2006-01-27 | 2011-09-07 | Tripath Imaging, Inc. | Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor |
| US20090275633A1 (en) | 2006-04-13 | 2009-11-05 | Oncomethylome Sciences Sa | Novel Tumour Suppressor |
| US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
| KR20090071603A (ko) * | 2006-09-19 | 2009-07-01 | 노파르티스 아게 | Ｒａｆ 억제제에 대한 표적 조절, 효능, 진단 및/또는 예후의 바이오마커 |
| US20090082218A1 (en) | 2007-08-13 | 2009-03-26 | Paul Harkin | 3'-Based sequencing approach for microarray manufacture |
| WO2009042814A1 (en) | 2007-09-25 | 2009-04-02 | Minerva Biotechnologies Corp. | Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| CN101910416A (zh) * | 2007-11-09 | 2010-12-08 | 健泰科生物技术公司 | 在癌症患者中诊断性使用的方法和组合物 |
| CA2707900A1 (en) | 2007-12-07 | 2009-06-18 | Oregon Health & Science University | Methods to determine if a subject will respond to a bcr-abl inhibitor |
| AU2009209251B8 (en) * | 2008-01-28 | 2015-03-26 | Medimmune Limited | Stabilized Angiopoietin-2 antibodies and uses thereof |
| US8114593B2 (en) | 2008-03-12 | 2012-02-14 | University Of Medicine And Dentistry Of New Jersey | Cancer biomarker genes and gene products and methods for using the same |
| WO2009149297A1 (en) | 2008-06-04 | 2009-12-10 | The Arizona Board Regents, On Behalf Of The University Of Arizona | Diffuse large b-cell lymphoma markers and uses therefor |
| US20110195064A1 (en) | 2008-06-06 | 2011-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Survival predictor for diffuse large b cell lymphoma |
| AU2009270851A1 (en) | 2008-07-16 | 2010-01-21 | Dana-Farber Cancer Institute, Inc. | Signatures and PCDETERMINANTS associated with prostate cancer and methods of use thereof |
| JP5606438B2 (ja) | 2008-07-23 | 2014-10-15 | エフ．ホフマン−ラ ロシュ アーゲー | 抗血管新生療法を受容可能な被験体の同定 |
| EA020764B1 (ru) | 2008-12-23 | 2015-01-30 | Мерк Патент Гмбх | Биомаркеры для ингибиторов с антиангиогенной активностью |
| WO2010088688A2 (en) | 2009-02-02 | 2010-08-05 | Biotheranostics, Inc. | Diagnosis of in situ and invasive breast cancer |
| SG10201401722XA (en) | 2009-05-01 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy |
| US7615353B1 (en) * | 2009-07-06 | 2009-11-10 | Aveo Pharmaceuticals, Inc. | Tivozanib response prediction |
| AU2010297344A1 (en) * | 2009-09-17 | 2012-02-23 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
| CA2811015A1 (en) | 2010-09-15 | 2012-03-22 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| WO2012052757A1 (en) | 2010-10-20 | 2012-04-26 | Astrazeneca Ab | Tumour phenotype patient selection method |
| US20130261018A1 (en) * | 2010-10-20 | 2013-10-03 | University Of Tennessee Research Foundation | Interferon gene signature and methods of use thereof |
| AU2011352167A1 (en) | 2010-12-28 | 2013-07-11 | Caris Mpi, Inc. | Molecular profiling for cancer |
| BR112013031019A2 (pt) * | 2011-06-02 | 2017-03-21 | Almac Diagnostics Ltd | teste diagnóstico molecular para câncer |
| KR20140114415A (ko) | 2012-01-13 | 2014-09-26 | 제넨테크, 인크. | Vegf 길항제로의 치료를 위한 환자를 확인하기 위한 생물학적 마커 |
| EP2667193A1 (en) | 2012-05-23 | 2013-11-27 | Université d'Aix-Marseille | MMP2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients |
| MX2015006955A (es) | 2012-12-03 | 2016-01-25 | Almac Diagnostics Ltd | Prueba de diagnostico molecular para cancer. |
-
2013
- 2013-12-03 MX MX2015006955A patent/MX2015006955A/es unknown
- 2013-12-03 WO PCT/GB2013/053202 patent/WO2014087156A1/en not_active Ceased
- 2013-12-03 EP EP13808178.1A patent/EP2925885B1/en active Active
- 2013-12-03 HK HK16102633.1A patent/HK1214633A1/zh unknown
- 2013-12-03 US US14/649,421 patent/US11091809B2/en not_active Expired - Fee Related
- 2013-12-03 KR KR1020157017703A patent/KR20150090246A/ko not_active Withdrawn
- 2013-12-03 SG SG11201504023SA patent/SG11201504023SA/en unknown
- 2013-12-03 AU AU2013353839A patent/AU2013353839A1/en not_active Abandoned
- 2013-12-03 JP JP2015544542A patent/JP2015536667A/ja active Pending
- 2013-12-03 CA CA2893033A patent/CA2893033A1/en not_active Abandoned
- 2013-12-03 CN CN201380071098.3A patent/CN105102631A/zh active Pending
-
2015
- 2015-06-03 IL IL239196A patent/IL239196A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015536667A5 (https=) | ||
| JP2017506506A5 (https=) | ||
| ES2821300T3 (es) | Predicción de pronóstico para el melanoma de cáncer | |
| JP2014516552A5 (https=) | ||
| CN103547682B (zh) | 肝细胞癌的基因标签 | |
| JP2015536667A (ja) | 癌のための分子診断検査 | |
| JP2011517932A5 (https=) | ||
| Linhares et al. | Genetic and immunohistochemical expression of integrins ITGAV, ITGA6, and ITGA3 as prognostic factor for colorectal cancer: models for global and disease-free survival | |
| Han et al. | The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma | |
| JP2015504677A5 (https=) | ||
| Won et al. | Autophagy is related to the hedgehog signaling pathway in human gastric adenocarcinoma: prognostic significance of Beclin-1 and Gli2 expression in human gastric adenocarcinoma | |
| Marcus et al. | Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model | |
| Doig et al. | Tumour mutational burden: an overview for pathologists | |
| Štemberger et al. | Osteopontin is associated with decreased apoptosis and αv integrin expression in lung adenocarcinoma | |
| Guler et al. | Fragile histidine triad protein, WW domain‐containing oxidoreductase protein Wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer | |
| Liu et al. | Prognosis and immunoinfiltration analysis of angiogene-related genes in grade 4 diffuse gliomas | |
| US20250101524A1 (en) | Compositions and methods for cell-free dna epigenetic gastrointestinal cancer detection and treatment | |
| US20170088902A1 (en) | Expression profiling for cancers treated with anti-angiogenic therapy | |
| Havekes et al. | Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas | |
| Weng et al. | Clinical significance of CENP-H expression in uterine cervical cancer | |
| Mehta et al. | Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade | |
| Settleman | Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK) | |
| Ghosh et al. | Inactivation of 9q22. 3 tumor suppressor genes predict outcome for patients with head and neck squamous cell carcinoma | |
| Dhawan | Biotechnology for biomarkers: Towards prediction, screening, diagnosis, prognosis, and therapy | |
| JP6478417B2 (ja) | 大腸癌患者の生存を予測及び改善するための方法 |